Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or Lecithin:Retinol Acyltransferase

Next Previous
Search
Trial Profile

Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or Lecithin:Retinol Acyltransferase

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 27 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Leber congenital amaurosis; Retinitis pigmentosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Retinagenix Therapeutics

    • Most Recent Events

    • 22 Feb 2023 Status changed from suspended to withdrawn prior to enrolment.
    • 22 Feb 2023 Planned initiation date changed from 1 May 2020 to 1 Dec 2020.
    • 07 Oct 2020 Status changed from not yet recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top